Vertex to acquire Alpine Immune Sciences for $4.9 bln-March 2024-www.financetom.com

Vertex to acquire Alpine Immune Sciences for $4.9 bln

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Vertex to acquire Alpine Immune Sciences for $4.9 bln

Apr 10, 2024 1:32 PM

April 10 (Reuters) - Vertex Pharmaceuticals ( VRTX )

will acquire Alpine Immune Sciences ( ALPN ) for $65 per share,

or about $4.9 billion in cash, the companies said on Wednesday.

Previous page： Incyte' Q4 Adjusted Earnings, Revenue Rise Next page： Hyatt to acquire Playa Hotels for $2.6 billion

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Incyte' Q4 Adjusted Earnings, Revenue Rise

Feb 10, 2025

07:16 AM EST, 02/10/2025 (MT Newswires) -- Incyte ( INCY ) reported Q4 non-GAAP earnings Monday of $1.43 per diluted share, compared with $1.06 a year earlier. Analysts surveyed by FactSet expected $1.49. Revenue for the quarter ended Dec. 31 was $1.18 billion, compared with $1.01 billion a year earlier. Analysts surveyed by FactSet expected $1.14 billion. Shares of Incyte...

Hyatt to acquire Playa Hotels for $2.6 billion

Feb 10, 2025

(Reuters) - Hyatt Hotels ( H ) will buy Playa Hotels & Resorts ( PLYA ) for about $2.6 billion including debt, net of cash, the company said on Monday, seeking to expand its presence in Mexico and the Caribbean. Playa operates resorts in Mexico, the Dominican Republic and Jamaica. Hyatt, which currently owns 9.4% of Playa's outstanding shares, expects...

Rockwell Automation's Fiscal Q1 Adjusted Earnings, Sales Fall; Fiscal 2025 Reported Revenue Midpoint Guidance Cut

Feb 10, 2025

07:18 AM EST, 02/10/2025 (MT Newswires) -- Rockwell Automation ( ROK ) reported fiscal Q1 adjusted earnings Monday of $1.83 per share, down from $2.04 a year earlier. Analysts polled by FactSet expected $1.58. Sales for the quarter ended Dec. 31 were $1.88 billion, down from $2.05 billion a year earlier. Analysts surveyed by FactSet expected $1.88 billion. The company...

Roivant Sciences Fiscal Q3 Earnings, Revenue Fall

Feb 10, 2025

07:16 AM EST, 02/10/2025 (MT Newswires) -- Roivant Sciences ( ROIV ) reported fiscal Q3 earnings Monday of $0.23 per diluted share, down from $6.03 a year earlier. Four analysts polled by FactSet expected a loss of $0.31. Revenue for the quarter ended Dec. 31 was $9 million, compared with $15.6 million a year earlier. Analysts surveyed by FactSet expected...